158 related articles for article (PubMed ID: 15742370)
1. Elevated fibroblast growth factor-23 in hypophosphatemic linear nevus sebaceous syndrome.
Hoffman WH; Jueppner HW; Deyoung BR; O'dorisio MS; Given KS
Am J Med Genet A; 2005 Apr; 134(3):233-6. PubMed ID: 15742370
[TBL] [Abstract][Full Text] [Related]
2. Matrix extracellular phosphoglycoprotein (MEPE) correlates with serum phosphorus prior to and during octreotide treatment and following excisional surgery in hypophosphatemic linear sebaceous nevus syndrome.
Hoffman WH; Jain A; Chen H; Fedarko NS
Am J Med Genet A; 2008 Aug; 146A(16):2164-8. PubMed ID: 18627046
[No Abstract] [Full Text] [Related]
3. Linear nevus sebaceous syndrome with hypophosphatemic rickets with elevated FGF-23.
Narazaki R; Ihara K; Namba N; Matsuzaki H; Ozono K; Hara T
Pediatr Nephrol; 2012 May; 27(5):861-3. PubMed ID: 22205508
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous skeletal hypophosphatemia syndrome (CSHS) is a multilineage somatic mosaic RASopathy.
Lim YH; Ovejero D; Derrick KM; ; Collins MT; Choate KA
J Am Acad Dermatol; 2016 Aug; 75(2):420-7. PubMed ID: 27444071
[TBL] [Abstract][Full Text] [Related]
5. Hypophosphatemic rickets/osteomalacia in linear sebaceous nevus syndrome: a variant of tumor-induced osteomalacia.
Carey DE; Drezner MK; Hamdan JA; Mange M; Ahmad MS; Mubarak S; Nyhan WL
J Pediatr; 1986 Dec; 109(6):994-1000. PubMed ID: 3023599
[TBL] [Abstract][Full Text] [Related]
6. Polyostotic osteolysis and hypophosphatemic rickets with elevated serum fibroblast growth factor 23: A case report.
Sato T; Muroya K; Asakura Y; Yachie A; Nishimura G; Aida N; Machida J; Tanaka Y; Hasegawa T; Adachi M
Am J Med Genet A; 2015 Oct; 167A(10):2430-4. PubMed ID: 26059403
[TBL] [Abstract][Full Text] [Related]
7. Tumor-Induced Osteomalacia and the Importance of Plasma Fibroblast Growth Factor 23 as an Indicator: Diagnostic Delay Leads to a Suicide Attempt.
Seemann L; Padala SA; Mohammed A; Belayneh N
J Investig Med High Impact Case Rep; 2019; 7():2324709619895162. PubMed ID: 31850815
[TBL] [Abstract][Full Text] [Related]
8. Linear sebaceous naevus syndrome and resistant rickets.
Hosalkar HS; Jones DH; Offiah A; Hall C
J Bone Joint Surg Br; 2003 May; 85(4):578-83. PubMed ID: 12793567
[TBL] [Abstract][Full Text] [Related]
9. Levels and dynamic changes of serum fibroblast growth factor 23 in hypophosphatemic rickets/osteomalacia.
Xia WB; Jiang Y; Li M; Xing XP; Wang O; Hu YY; Zhang HB; Liu HC; Meng XW; Zhou XY
Chin Med J (Engl); 2010 May; 123(9):1158-62. PubMed ID: 20529556
[TBL] [Abstract][Full Text] [Related]
10. Postzygotic HRAS mutation causing both keratinocytic epidermal nevus and thymoma and associated with bone dysplasia and hypophosphatemia due to elevated FGF23.
Avitan-Hersh E; Tatur S; Indelman M; Gepstein V; Shreter R; Hershkovitz D; Brick R; Bergman R; Tiosano D
J Clin Endocrinol Metab; 2014 Jan; 99(1):E132-6. PubMed ID: 24243633
[TBL] [Abstract][Full Text] [Related]
11. Epidermal nevus syndrome associated with hypophosphatemic rickets.
Moreira AI; Ferreira G; Santos M; Baptista A; Ferreira EO
Dermatol Online J; 2010 Sep; 16(9):14. PubMed ID: 20875335
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment with MEK-inhibitor in a patient with NRAS-related cutaneous skeletal hypophosphatemia syndrome.
Carli D; Cardaropoli S; Tessaris D; Coppo P; La Selva R; Cesario C; Lepri FR; Pullano V; Palumbo M; Ramenghi U; Brusco A; Medico E; De Sanctis L; Ferrero GB; Mussa A
Genes Chromosomes Cancer; 2022 Dec; 61(12):740-746. PubMed ID: 35999193
[TBL] [Abstract][Full Text] [Related]
13. The levels of somatostatin receptors in causative tumors of oncogenic osteomalacia are insufficient for their agonist to normalize serum phosphate levels.
Ishii A; Imanishi Y; Kobayashi K; Hashimoto J; Ueda T; Miyauchi A; Koyano HM; Kaji H; Saito T; Oba K; Komatsu Y; Kurajoh M; Nagata Y; Goto H; Wakasa K; Sugimoto T; Miki T; Inaba M; Nishizawa Y
Calcif Tissue Int; 2010 Jun; 86(6):455-62. PubMed ID: 20458578
[TBL] [Abstract][Full Text] [Related]
14. Cinacalcet in the management of tumor-induced osteomalacia.
Geller JL; Khosravi A; Kelly MH; Riminucci M; Adams JS; Collins MT
J Bone Miner Res; 2007 Jun; 22(6):931-7. PubMed ID: 17352646
[TBL] [Abstract][Full Text] [Related]
15. Post-transplant hypophosphatemia: Tertiary 'Hyper-Phosphatoninism'?
Bhan I; Shah A; Holmes J; Isakova T; Gutierrez O; Burnett SM; Jüppner H; Wolf M
Kidney Int; 2006 Oct; 70(8):1486-94. PubMed ID: 16941023
[TBL] [Abstract][Full Text] [Related]
16. [Linear nevus sebaceous syndrome with hemimegalencephaly diagnosed in child in neonatal period].
Jachowicz-Jeszka J; Juchniewicz B; Rotsztejn H; Wilkowski J; Wendorff J
Pol Merkur Lekarski; 2005 Mar; 18(105):310-3. PubMed ID: 15997640
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous Skeletal Hypophosphatemia Syndrome in Association with a Mosaic
Park PG; Park E; Hyun HS; Kang HG; Ha IS; Cho TJ; Ko JM; Cheong HI
Ann Clin Lab Sci; 2018 Sep; 48(5):665-669. PubMed ID: 30373874
[TBL] [Abstract][Full Text] [Related]
18. New insights into phosphate homeostasis: fibroblast growth factor 23 and frizzled-related protein-4 are phosphaturic factors derived from tumors associated with osteomalacia.
Kumar R
Curr Opin Nephrol Hypertens; 2002 Sep; 11(5):547-53. PubMed ID: 12187320
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous skeletal hypophosphatemia syndrome: clinical spectrum, natural history, and treatment.
Ovejero D; Lim YH; Boyce AM; Gafni RI; McCarthy E; Nguyen TA; Eichenfield LF; DeKlotz CM; Guthrie LC; Tosi LL; Thornton PS; Choate KA; Collins MT
Osteoporos Int; 2016 Dec; 27(12):3615-3626. PubMed ID: 27497815
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.
Jonsson KB; Zahradnik R; Larsson T; White KE; Sugimoto T; Imanishi Y; Yamamoto T; Hampson G; Koshiyama H; Ljunggren O; Oba K; Yang IM; Miyauchi A; Econs MJ; Lavigne J; Jüppner H
N Engl J Med; 2003 Apr; 348(17):1656-63. PubMed ID: 12711740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
